

In The Claims

Please amend claims 17-19, 21, 26, 29 and 42-44 as follows:

1.-16. (Canceled)

17. (currently amended) An isolated polypeptide encoded by ~~the~~ a nucleic acid sequence ~~comprising~~ consisting of the sequence from nucleotide number 1 to nucleotide number 3201 of SEQ ID NO:2.

18. (currently amended) An isolated polypeptide encoded by ~~the~~ a nucleic acid sequence ~~comprising~~ consisting of the sequence of SEQ ID NO:17.

19. (currently amended) The isolated polypeptide of claim 17, wherein said polypeptide ~~comprises~~ consists of the amino acid sequence of SEQ ID NO:18.

20. (Canceled)

21. (currently amended) The isolated polypeptide of claim 17, wherein the amino acid sequence of said polypeptide ~~comprises~~ consists of ~~from~~ amino acid residue 1 to amino acid residue 1067 of the sequence of SEQ ID NO:1.

22. (Original) The isolated polypeptide of claim 17, said polypeptide further comprising a tag polypeptide.

23. (Previously presented) The isolated polypeptide of claim 22, wherein said tag polypeptide is selected from the group consisting of a myc tag polypeptide, a myc-pyruvate kinase tag polypeptide, a glutathione-S-transferase tag polypeptide, a maltose binding tag polypeptide, a green fluorescence protein tag polypeptide, an alkaline phosphatase tag polypeptide, a His6 tag polypeptide, an influenza virus hemagglutinin tag polypeptide, and a maltose binding protein tag polypeptide.

24. (Original) The isolated polypeptide of claim 23, wherein said tag polypeptide is a myc tag polypeptide.

25. (Withdrawn) A recombinant cell comprising the isolated soluble Jagged polypeptide of claim 17.

26. (currently amended) A composition comprising ~~an~~ the isolated soluble Jagged polypeptide consisting of the sequence set forth in SEQ ID NO:18 in a pharmaceutically acceptable carrier.

27-28. (Canceled).

29. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of an isolated soluble Jagged polypeptide, wherein said polypeptide ~~comprises~~ consists of the sequence of SEQ ID NO:18, in a pharmaceutically acceptable carrier.

30. (Withdrawn) A pharmaceutical composition comprising a recombinant cell comprising an isolated nucleic acid encoding a soluble Jagged polypeptide in a pharmaceutically acceptable carrier, wherein said isolated nucleic acid comprises the sequence of SEQ ID NO:17.

31. (Withdrawn) A pharmaceutical composition comprising a recombinant cell comprising an isolated soluble Jagged polypeptide, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:18.

32-41. (Canceled).

42. (currently amended) A kit for affecting angiogenesis in a mammal, said kit comprising an angiogenic effective amount of an isolated soluble Jagged polypeptide, wherein said polypeptide ~~comprises~~ consists of the amino acid sequence of SEQ ID NO:18, an applicator, and an instructional material for the use of said kit.

43. (currently amended) A kit for affecting differentiation of a cell, said kit comprising a differentiation effective amount of an isolated soluble Jagged polypeptide, an applicator, and an instructional material for the use of said kit, wherein said polypeptide ~~comprises~~ consists of the amino acid sequence of SEQ ID NO:18.

44. (currently amended) A kit for inhibiting expression of type I collagen in a cell, said kit comprising an expression inhibiting amount of an isolated soluble Jagged polypeptide, an applicator, and an instructional material for the use of said kit, wherein said polypeptide ~~comprises~~ consists of the amino acid sequence of SEQ ID NO:18.